Suzuki Keita, Tsujiguchi Hiromasa, Hara Akinori, Pham Oanh Kim, Miyagi Sakae, Nguyen Thao Thi Thu, Nakamura Haruki, Suzuki Fumihiko, Kasahara Tomoko, Shimizu Yukari, Yamada Yohei, Kambayashi Yasuhiro, Tsuboi Hirohito, Sato Takehiro, Kannon Takayuki, Hosomichi Kazuyoshi, Tajima Atsushi, Takamura Toshinari, Nakamura Hiroyuki
Department of Hygiene and Public Health, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan.
Department of Public Health, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan.
J Pain Res. 2022 May 23;15:1475-1485. doi: 10.2147/JPR.S356630. eCollection 2022.
Previous studies examined the association between chronic pain (CP) and serum 25-hydroxyvitamin D (25(OH)D) concentrations; however, the findings obtained were inconsistent. Single nucleotide polymorphisms (SNP) associated with the transcriptional activity of the vitamin D receptor () gene may influence the association of 25(OH)D levels with CP. We aimed to clarify the association between CP, serum 25(OH)D concentration, and SNPs.
In the Shika study, we performed a cross-sectional analysis of 551 participants older than 40 years who were asked whether they had been having persistent pain lasting for at least 3 months in any part of the body on a self-administered questionnaire. Serum 25(OH)D concentrations were assessed as a biomarker of the vitamin D status using a radioimmunoassay. rs731236, rs7975232, rs1544410, rs2228570, and rs11568820 were identified using peripheral blood samples, and participants were assigned to those with or without the minor allele for each SNP.
The prevalence of CP was 37.2%. We observed a tendency for lower 25(OH)D levels in participants with CP than in those without CP in the hetero/minor group of rs11568820, which is a polymorphism within the CDX2-binding site in the 1e promoter region of the gene. Furthermore, a logistic regression analysis revealed that lower serum 25(OH)D concentrations were significantly associated with CP in the hetero/minor group, but not in the major group.
These results suggest that sufficient serum 25(OH)D concentration reduces the risk of CP in individuals with the minor allele of the CDX2 polymorphism.
既往研究探讨了慢性疼痛（CP）与血清25-羟维生素D（25(OH)D）浓度之间的关联；然而，所得结果并不一致。与维生素D受体（VDR）基因转录活性相关的单核苷酸多态性（SNP）可能会影响25(OH)D水平与CP之间的关联。我们旨在阐明CP、血清25(OH)D浓度和SNP之间的关联。
在志贺研究中，我们对551名40岁以上的参与者进行了横断面分析，这些参与者通过自行填写问卷被问及身体任何部位是否存在持续至少3个月的持续性疼痛。使用放射免疫分析法评估血清25(OH)D浓度作为维生素D状态的生物标志物。通过外周血样本鉴定rs731236、rs7975232、rs1544410、rs2228570和rs11568820，并将参与者按每个SNP的次要等位基因有无进行分组。
CP的患病率为37.2%。在rs11568820的杂合/次要等位基因组中，我们观察到CP患者的25(OH)D水平有低于无CP患者的趋势，rs11568820是VDR基因1α启动子区域中CDX2结合位点内的多态性。此外，逻辑回归分析显示，较低的血清25(OH)D浓度在杂合/次要等位基因组中与CP显著相关，但在主要等位基因组中则不然。
这些结果表明，血清25(OH)D浓度充足可降低携带CDX2多态性次要等位基因个体患CP的风险。
